Table 2 Outcomes
From: Impact of frontline treatment approach on outcomes of myeloid blast phase CML
| Characteristic | N (%); Median [Range] | |||
|---|---|---|---|---|
|
IC + TKI (N = 20) | HMA + TKI (N = 20) |
TKI (N = 56) |
IC (N = 8) | |
| Best response | ||||
| CR | 9 (45%) | 6 (30%) | 12 (21.4%) | 0 |
| CRi | 3 (15%) | 5 (25%) | 7 (12.5%) | 1 (12.5%) |
| MLFS | 4 (20%) | 3 (15%) | 8 (14.3%) | 0 |
| PR | 0 | 0 | 1 (1.8%) | 0 |
| No response | 4 (20%) | 6 (30%) | 28 (50%) | 7 (87.5%) |
| CR/CRi | 12 (60%) | 11 (55%) | 19 (33.9%) | 1 (12.5%) |
| ORR (CR/CRi/MLFS) | 16 (80%) | 14 (70%) | 27 (48.2%) | 1 (12.5%) |
| Complete cytogenetic remission | 8 (40%) | 10 (50%) | 6 (10.7%) | 0 |
| Best molecular response^ | ||||
| MMR | 2/17 (11.7%) | 1/16 (6.3%) | 1/47 (2.1%) | 0 |
| MR4 | 2/17 (11.7%) | 2/16 (12.5%) | 0 | 0 |
| MR4.5 | 1/17 (5.9%) | 0 | 1/47 (2.1%) | 0 |
| Time to best response (months) |
0.9 [0.7–6.9] |
2.2 [0.8–5.5] |
2.1 [0.6–16.3] |
0.6 [0.6–0.6] |
| Proceeded to ASCT on this regimen | 7 (35%) | 6 (30%) | 6* (10.7%) | 1 (12.5%) |
| Median time to ASCT (months) | 3.4 [1.5–7.9] | 5.7 [2.9–8] | 3.5 [2.5–5.7] | 1.3 [1.3–1.3] |
| Median EFS (months) |
5.2 [0.8–160.7] |
5.0 [1.2–96.1] |
4.8 [0.5–129.6] |
2.2 [0.8–4.1] |
| Median RFS (months) |
5.5 [0.5–159.8] |
4.7 [0.6–93.5] |
4.6 [0.2–127.7] |
3.5 [3.5–3.5] |
| Median OS (months) |
12.9 [0.8–160.7] |
10.1 [1.2–96.1] |
10.7 [0.5–244.3] |
3.4 [0.8–48.9] |
| Relapse after initial objective response | 6/16 | 6/14 | 17/27 | 0/1 |
| EM relapse** | 3/6 (50%) | 1/6 (16.7%) | 3/17 (17.6%) | 0/1 (0%) |
| Early mortality | ||||
| 30-day mortality | 1 (5%) | 0 | 1 (1.8%) | 1 (12.5%) |
| 60-day mortality | 3 (15%) | 2 (10%) | 1 (1.8%) | 3 (37.5%) |
| 5-year rates | ||||
| CIR | 51% | 54% | 80% | 100% |
| EFS | 27% | 19% | 5% | 0% |
| OS | 30% | 28% | 13% | 0% |